Evidence map›Paper›PMID 28357697›Full record

ArticleDigestive diseases and sciences2017

Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab.

Jessica R Allegretti, Edward L Barnes, Betsey Stevens, Margaret Storm, Ashwin Ananthakrishnan, Vijay Yajnik, Joshua Korzenik

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases and sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. [Advanced Combination Therapy in Inflammatory Bowel Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Observational
  12. Refractory Crohn's Disease: Perspectives, Unmet Needs and Innovations.Clinical and experimental gastroenterology · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jessica R AllegrettiDivision of Gastroenterology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02141, USA. jallegretti@bwh.harvard.edu.
Edward L BarnesDivision of Gastroenterology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02141, USA.
Betsey StevensGastroenterology Unit, Massachusetts General Hospital, Boston, MA, USA.
Margaret StormDivision of Gastroenterology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02141, USA.
Ashwin AnanthakrishnanGastroenterology Unit, Massachusetts General Hospital, Boston, MA, USA.
Vijay YajnikGastroenterology Unit, Massachusetts General Hospital, Boston, MA, USA.
Joshua KorzenikDivision of Gastroenterology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02141, USA.

Funding

Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3M
NIDDK NIH HHS P30 DK043351
6 · The paper itself

Abstract

backgroundVedolizumab (VDZ) has demonstrated long-term efficacy in Crohn's disease (CD) and ulcerative colitis (UC) in phase III trials.

aimsOur aim was to evaluate the efficacy of VDZ at week 54 in inflammatory bowel disease (IBD) in a multicenter cohort of patients.

methodsAdult patients completing induction therapy with VDZ were eligible for this study. Clinical response and remission was assessed using the Harvey-Bradshaw Index (HBI) for CD, the Simple Clinical Colitis Activity Index for UC and physician assessment.

resultsAmong 136 total patients (96 CD and 40 UC), 76 (56%) demonstrated clinical response or remission at week 54. In univariate analysis, for patients with CD concomitant initiation of immunomodulator therapy (2.71, 95% CI 1.11-6.57), the addition of an immunomodulator (OR 11.49, 3.16-41.75) and CRP < 3 (4.92, 95% CI 1.99-12.15) was associated with increased odds of clinical response or remission at week 54. For UC patients, hospitalization after VDZ induction was associated with decreased odds of response or remission at week 54 (OR 0.22, 95% CI 0.05-0.88). On multivariate analysis in CD, addition of an immunomodulator (OR 8.33, 95% CI 2.15-32.26) remained significant predictors of clinical response or remission at week 54.

conclusionsAmong a multicenter cohort of patients with IBD demonstrating primary response to VDZ, the addition of combination therapy with an immunomodulator is a significant predictor of clinical response or remission at week 54 in patients with CD.

Indexed as

AdultAntibodies, Monoclonal, HumanizedColitis, UlcerativeC-Reactive ProteinCrohn DiseaseDrug Therapy, CombinationFemaleGastrointestinal AgentsHospitalizationHumansImmunologic FactorsMaleMiddle AgedRemission InductionRetrospective StudiesSeverity of Illness IndexAntibodies, Monoclonal, HumanizedC-Reactive ProteinGastrointestinal AgentsImmunologic FactorsvedolizumabCombination therapyCrohn’s diseaseImmunomodulatorInflammatory bowel diseaseUlcerative colitisVedolizumab

Identifiers

PMID28357697
PMCPMC5661939

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.